Patents by Inventor David Brems
David Brems has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11607451Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: GrantFiled: March 12, 2013Date of Patent: March 21, 2023Assignee: Amgen Inc.Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, Jr., David Brems, Susan Irene Hershenson
-
Publication number: 20190345238Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.Type: ApplicationFiled: May 22, 2019Publication date: November 14, 2019Applicant: AMGEN INC.Inventors: Jaby JACOB, Masazumi MATSUMURA, Yatin GOKARN, David BREMS
-
Publication number: 20170368170Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention farther provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: September 7, 2017Publication date: December 28, 2017Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160367665Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that arc suitable for veterinary and human medical use, The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 9, 2016Publication date: December 22, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160367666Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160362486Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 8, 2016Publication date: December 15, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160362485Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that arc suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 5, 2016Publication date: December 15, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160362484Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 3, 2016Publication date: December 15, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160339102Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 4, 2016Publication date: November 24, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160319011Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: July 19, 2016Publication date: November 3, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20150315271Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.Type: ApplicationFiled: May 5, 2015Publication date: November 5, 2015Applicant: AMGEN INC.Inventors: Jaby JACOB, Masazumi MATSUMURA, Yatin GOKARN, David BREMS
-
Publication number: 20130273066Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: March 12, 2013Publication date: October 17, 2013Inventors: Yatin R. GOKARN, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20130273067Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: March 12, 2013Publication date: October 17, 2013Inventors: Yatin R. GOKARN, Eva KRAS, Richard Louis REMMELE, JR., David BREMS, Susan Irene HERSHENSON
-
Publication number: 20120028877Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: July 21, 2011Publication date: February 2, 2012Applicant: Amgen Inc.Inventors: Yatin R. GOKARN, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20080311078Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: June 8, 2006Publication date: December 18, 2008Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, David Brems, Susan Irene Hershenson
-
Publication number: 20080213282Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.Type: ApplicationFiled: December 19, 2007Publication date: September 4, 2008Inventors: Jaby Jacob, Masazumi Matsumura, Yatin Gokarn, David Brems
-
Patent number: 5874075Abstract: The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss of activity. The protein:phospholipid complex directly stabilizes the secondary and tertiary structure of the protein, and the compositions are useful in high temperature formulations and in novel delivery vehicles.Type: GrantFiled: March 31, 1995Date of Patent: February 23, 1999Assignee: Amgen Inc.Inventors: David Collins, Younsik Cha, David Brems